First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.

BACKGROUND In a phase III randomized trial, we compared the effectiveness and tolerability of fadrozole (CGS 16949A), a non-steroidal aromatase inhibitor, to tamoxifen as first-line endocrine therapy in postmenopausal women with advanced breast cancer. PATIENTS AND METHODS Two hundred twelve eligible patients were randomized to receive tamoxifen 20 mg daily, or fadrozole 1 mg twice daily orally until disease progression or the advent of undue toxicity. The treatments were to be discontinued upon disease progression. RESULTS Prognostic factors were well balanced between the treatment groups, except for sites of metastatic disease. Fadrozole-treated patients had significantly more visceral, especially liver, involvement and less bone-dominant disease. Response rates for fadrozole and tamoxifen were similar, 20% and 27% (95% Confidence Limits (CL): 13%-29% and 21%-35%), respectively. Time to treatment failure was longer in patients randomized to tamoxifen (8.5 months for tamoxifen vs. 6.1 months for fadrozole), but did not reach statistical significance after adjustment for prognostic factors (P = 0.09). Fadrozole, for which a significantly lower percentage of clinically relevant toxic effects (WHO toxicity grade > or = 2) was recorded (27% vs. 13%, respectively; P = 0.009), was better tolerated than tamoxifen. Severe cardiovascular events including 3 fatalities were seen only in patients treated with tamoxifen. Eighty-two patients crossed over to tamoxifen and 66 patients to fadrozole. Crossover endocrine therapy led to response or stable disease in 64% of the patients. The overall survival times of the two treatment groups were similar. CONCLUSIONS Fadrozole and tamoxifen showed similar efficacy as first-line treatments in postmenopausal patients with advanced breast cancer. Fadrozole was significantly better tolerated and may therefore be an appropriate alternative to tamoxifen, especially for patients predisposed to thromboembolic events.

[1]  J. Wolter,et al.  Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen , 1994, Cancer.

[2]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[3]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[4]  S. Dahrouge,et al.  Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. , 1990, Seminars in oncology.

[5]  F. Cavalli,et al.  Original article: CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer — A Phase I study , 1990 .

[6]  J. Fishman.  Biochemical mechanism of aromatization. , 1982, Cancer research.

[7]  K. E. Gale.  Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience. , 1982, Cancer research.

[8]  K. Boo-Chai.  Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomised cross‐over trial , 1982 .

[9]  M. Palmer,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.

[10]  A. Harris,et al.  Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. , 1981, British medical journal.

[11]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[12]  K. Ryan,et al.  Aromatization of androgens by human abdominal and breast fat tissue. , 1975, The Journal of clinical endocrinology and metabolism.

[13]  J. Thijssen,et al.  Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. , 1973, The Journal of clinical endocrinology and metabolism.

[14]  D. Cox,et al.  The analysis of binary data , 1971 .

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  J. Firmat,et al.  [Endocrine therapy of metastatic breast cancer]. , 1958, Revista argentina de endocrinologia y metabolismo.

[17]  N. Treves,et al.  Endocrine therapy of metastatic breast cancer. , 1955, A.M.A. archives of internal medicine.

[18]  T. Delozier,et al.  Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Raats,et al.  A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Cavalli,et al.  CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[22]  D.,et al.  Regression Models and Life-Tables , 2022 .